Standard of Care Chemotherapy Clinical Trials

4 actively recruiting trials across 2 locations

No change since May 2026

Also known as: Cisplatin, best practice, carboplatin, standard of care, standard therapy

Pipeline

Phase 2: 1Phase 3: 2Phase 2/3: 1

Top Sponsors

Intergroupe Francophone de Cancerologie Thoracique1
Institut Claudius Regaud1
ECOG-ACRIN Cancer Research Group1
Dana-Farber Cancer Institute1

Indications

Cancer4
HER2 Gene Mutation1
Neuroendocrine Carcinoma1
Gastroesophageal Junction Adenocarcinoma1
Gastric Adenocarcinoma1

Other2 trials

Interest of Peri Operative CHemotherapy In Patients With CINSARC High-risk Localized Soft Tissue Sarcoma

Phase 3

Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs)

Phase 3

Irvine, California1 trial

Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity

UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care

Phase 2/3

Atlanta, Georgia1 trial

Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas

Winship Cancer Institute, Emory University

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.